The aim is to assess effectiveness (EASI, SCORAD, IGA, DLQI, pruritus, sleep loss) and safety (clinical and biological adverse events) of JAK inhibitors in adults with moderate-to-severe atopic dermatitis in a real-life French multicenter retrospective cohort
Study Type
OBSERVATIONAL
Hop Claude Huriez Chu Lille
Lisle-sur-Tarn, France
reduction in Eczema Area and Severity Index (EASI)
Time frame: At 3 months
SCORing Atopic Dermatitis (SCORAD)
Time frame: at baseline and at 3 months
Investigator's Global Assessment (IGA)
Time frame: at baseline and at 3 months
Dermatology Life Quality Index (DLQI)
Time frame: at baseline and at 3 months
patient-reported pruritus score from 0 to 10
Time frame: at baseline and at 3 months
patient-reported sleep loss from 0 to 10
Time frame: at baseline and at 3 months
Adverse effects (biological and clinical)
Time frame: at baseline and at 3 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.